Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

by Dominique Xavier Brown, Marc Evans
Published 2012-01-01

An Evaluation of Researcher Motivations and Productivity Outcomes in International Collaboration and Partnerships at a U.S. Research-Intensive University

by Jane Payumo, Danna Moore, Marc Evans, Prema Arasu
Published 2019-08-01

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with...

by Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, Jack Lawson, Abby Paine, Anna Sandberg
Published 2021-07-01

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

by Marc Evans, Eirini Palaka, Hans Furuland, Hayley Bennett, Cecilia Linde, Lei Qin, Phil McEwan, Ameet Bakhai
Published 2019-01-01

Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

by Hans Furuland, Phil McEwan, Marc Evans, Cecilia Linde, Daniel Ayoubkhani, Ameet Bakhai, Eirini Palaka, Hayley Bennett, Lei Qin
Published 2018-08-01

Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes.

by Kirsty C McGee, Alison L Harte, Nancy F da Silva, Nasser Al-Daghri, Steven J Creely, Christine M Kusminski, Gyanendra Tripathi, Paul L Levick, Manish Khanolkar, Marc Evans, Madhu V Chittari, Vinod Patel, Sudhesh Kumar, Philip G McTernan
Published 2011-01-01